# Translational and Clinical Aspects of Metabolic, Anabolic and Endothelial Dysfunction in Heart Failure

> **NCT05277415** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lars Lund** · enrollment: 31 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction HFrEF

## Interventions

- **BIOLOGICAL:** Ghrelin
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05277415
- **Lead sponsor:** Lars Lund
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-17
- **Primary completion:** 2014-05-22
- **Final completion:** 2014-05-22
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05277415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05277415, "Translational and Clinical Aspects of Metabolic, Anabolic and Endothelial Dysfunction in Heart Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05277415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*